left-arrow right-arrow pinterest facebook google_plus linkedin

Urinary Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


Alliance A031102

Status: Recruiting | Phase III

Official Title: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors.

Study Purpose: To determine if giving high dose chemotherapy and having a stem cell transplant will prevent or lengthen the time the time to recurrence when compared to the usual treatment of chemotherapy. Learn more.


Alliance A031702

Status: Suspended | Phase II

Official Title: Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors.

Study Purpose: The purpose of this study is study is to test the good and bad effects of the drugs cabozantinib, nivolumab, and ipilimumab in rare genitourinary cancers that have no standard treatment options. The doctors hope to learn if the study drugs will stabilize or shrink the cancer. Learn more

 


Alliance A031704

Status: Recruiting | Phase III

Official Title: Immunotherapy with nivolumab and ipilimumab followed by nivolumab or nivolumab with cabozantinib for patients with advanced kidney cancer

Study Purpose: The purpose of this study is to see how well nivolumab and ipilimumab, followed by nivolumab versus cabozantinib and nivolumab, work in treating patients with renal cell cancer that is untreated and has spread to other parts of the body. Learn more


AFT-19

Status: Recruiting | Phase III 

Official Title: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer.

Study Purpose: To compare progression free survival and overall survival of patients who receive the standard hormone therapy degarelix verses patients who receive degarelix and apalutamide versus patients who receive degarelix, apalutamide, abiraterone, and prednisone. Learn more.


ECOG-ACRIN EA8143

Status: Recruiting | Phase III 

Official Title: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC).

Study Purpose: To compare the rate that cancer returns in patients who have locally advanced renal cell carcinoma who either get standard of care observation after kidney removal or patients who receive nivolumab before and after surgery. Learn more.


HCRN GU17-289

Status: Recruiting | Phase II

Official Title: A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma

Study Purpose: To determine if adding entinostat, a drug that helps treat cancer, to the standard treatment for advanced kidney cancer will control the cancer longer than the standard treatment alone. Learn more.


HCRN GU17-295

Status: Recruiting | Phase II

Official Title: A Phase II Trial of Atezolizumab plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Study Purpose: The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 inhibitor. Learn more


NRG-GU002

Status: Recruiting | Phase II-III

Official Title: Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel.

Study Purpose: To assess the impact Docetaxel has on the survival of patients who received radiation and hormone therapy after prostate removal. Learn more.


NRG-GU006

Status: Recruiting | Phase II 

Official Title: A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer.

Study Purpose: To determine if adding apalutamide, a hormone therapy, to radiation treatment for patients with prostate cancer that was previously treated but is now detected in blood will allow patients to do better and live longer. Learn more.


Pharmacyclics PCYC-1128-CA

Status: Recruiting | Phase II

Official Title: A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors

Study Purpose: To determine if adding ibrutinib, a chemotherapy drug used to treat other cancers, to the standard treatment of bladder cancer or kidney cancer, will improve the survival.  Though this study is also looking into the use of ibrutinib in patients with colorectal cancer and gastric cancer, those groups are not enrolling patients at this time. Learn more.


SWOG S1500

Status: Recruiting | Phase II 

Official Title: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Study Purpose: To compare the survival in patients with papillary renal cell carcinoma (a type of kidney cancer) who a treated with either sunitinib, cabozantinib, savolitinib, or crizotinib.  This study will also be comparing the side effects patients experience on each of these drugs as well. Learn more.


SWOG S1802

Status: Recruiting |Phase III

Official Title: Comparing the Treatment Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy in Combination with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer

Study Purpose: To compare the effects, good and/or bad, of adding prostate removal surgery or radiation therapy to standard therapy which is used to treat prostate cancer. Learn more.


SWOG S1806

Status: Recruiting | Phase III

Official Title: Testing Combined Chemotherapy and Radiation Therapy With and Without the Use of Atezolizumab Immunotherapy in Muscle Invasive Bladder Cancer

Study Purpose: To compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of the immunotherapy drug atezolizumab, used to treat bladder cancer. Learn more